Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Anlotinib is named as an intervention in 59 current clinical trials in our China register. 32 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Sun Yat-sen University (7). The most-studied condition is Breast Cancer.

Trials by status

Recruiting3254%
Not yet open1932%
Active, closed814%

Trials by phase

Phase 24169%
Phase 3610%
Phase 447%
Phase 1/235%
Not applicable23%
Phase 2/323%
Phase 112%

Clinical trials of Anlotinib

59 trials

Study	Phase	Status	Lead sponsor	Registers
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma NCT06506838 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma, Doxorubicin, Radiotherapy	Phase 4	Recruiting	Guangdong Provincial People's Hospital	China
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance NCT06043973 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer	Phase 3	Recruiting	Qianfoshan Hospital	China
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. NCT07443397 · ClinicalTrials.gov ↗ · Whole-Brain Radiotherapy	Phase 3	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma NCT06354530 · ClinicalTrials.gov ↗ · Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma	Phase 2/3	Recruiting	Army Medical Center of PLA	China
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma NCT05188859 · ClinicalTrials.gov ↗ · Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer NCT05817214 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2	Recruiting	Zhongnan Hospital	China
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer NCT06141226 · ClinicalTrials.gov ↗ · Non-small-cell Lung Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC NCT06348927 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Hunan Province Tumor Hospital	China
To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer NCT06352008 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW NCT06355609 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Hunan Province Tumor Hospital	China
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer NCT06482086 · ClinicalTrials.gov ↗ · Locally Advanced Thyroid Gland Carcinoma	Phase 2	Recruiting	West China Hospital	China
Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy NCT06586242 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	Xijing Hospital	China
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion NCT06739395 · ClinicalTrials.gov ↗ · Solid Tumor, Precision Medicine	Phase 2	Recruiting	Tianjin Medical University Second Hospital	China
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults NCT06761417 · ClinicalTrials.gov ↗ · Solid Tumors, Children, Adolescents	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma NCT06838910 · ClinicalTrials.gov ↗ · Thymic Carcinoma, Thymoma	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma. NCT06851247 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis NCT06945705 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Recruiting	Henan Cancer Hospital	China
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy NCT06992336 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer NCT07025174 · ClinicalTrials.gov ↗ · Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT NCT07037680 · ClinicalTrials.gov ↗ · Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy, Safety	Phase 2	Recruiting	JIANYANG WANG	China
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy NCT07330544 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Zhejiang Cancer Hospital	China
MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma NCT07359053 · ClinicalTrials.gov ↗ · Sarcoma	Phase 2	Recruiting	Shanghai 6th People's Hospital	China
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC NCT07562581 · ClinicalTrials.gov ↗ · Non-small Cell Lung Caner, KRAS-mutated, Metastasis	Phase 2	Recruiting	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	China
QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer NCT07601178 · ClinicalTrials.gov ↗ · TNBC, Triple Negative Breast Cancer	Phase 2	Recruiting	Jiangsu Cancer Institute & Hospital	China
Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study NCT07806292 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC NCT07815223 · ClinicalTrials.gov ↗ · SCLC, Limited Stage	Phase 2	Recruiting	Yantai Yuhuangding Hospital	China
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer NCT06761027 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer	Phase 1/2	Recruiting	Fujian Provincial Hospital	China
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma NCT06970145 · ClinicalTrials.gov ↗ · Craniopharyngiomas	Phase 1/2	Recruiting	Nanfang Hospital, Southern Medical University	China
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer NCT06331169 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1	Recruiting	Fudan University	China
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC NCT06258642 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Recurrent	Not applicable	Recruiting	Fudan University	China
Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC) NCT07627347 · ClinicalTrials.gov ↗ · ESCC	Not applicable	Recruiting	Nanfang Hospital, Southern Medical University	China
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer NCT06931145 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer	Phase 4	Not yet open	Peking Union Medical College Hospital	China
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction NCT06951841 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 4	Not yet open	China Medical University, China	China
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study NCT07010393 · ClinicalTrials.gov ↗ · Thyroid Neoplasms	Phase 4	Not yet open	Fujian Medical University	China
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients NCT06469879 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Limited Stage	Phase 3	Not yet open	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China
A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT07446335 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma	Phase 3	Not yet open	The First Affiliated Hospital of Zhengzhou University	China
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. NCT07540390 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Not yet open	Sun Yat-sen University	China
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment NCT06662877 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Second Line Treatment, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) NCT06621095 · ClinicalTrials.gov ↗ · Pancreatic Cancer, First-line, Metastatic Pancreatic Cancer	Phase 2	Not yet open	RenJi Hospital	China
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance NCT06634667 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Not yet open	Hunan Province Tumor Hospital	China
Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC) NCT06681285 · ClinicalTrials.gov ↗ · Esophageal Carcinoma	Phase 2	Not yet open	Hebei Medical University Fourth Hospital	China
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC NCT06699498 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children NCT07137884 · ClinicalTrials.gov ↗ · Rhabdomyosarcoma Recurrent, Maintenance Treatment	Phase 2	Not yet open	Sun Yat-sen University	China
A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma NCT07355855 · ClinicalTrials.gov ↗ · Rhabdomyosarcoma	Phase 2	Not yet open	Fudan University	China
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma NCT07470840 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Renal Cell Carcinoma	Phase 2	Not yet open	Fujian Cancer Hospital	China
A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC NCT07510594 · ClinicalTrials.gov ↗ · Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma NCT07616141 · ClinicalTrials.gov ↗ · Adenoid Cystic Carcinoma	Phase 2	Not yet open	Eye & ENT Hospital of Fudan University	China
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases NCT07745257 · ClinicalTrials.gov ↗ · HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases	Phase 2	Not yet open	Sun Yat-sen University	China
The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT07780578 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line	Phase 2	Not yet open	Fudan University	China
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer NCT07139470 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 1/2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer NCT04523272 · ClinicalTrials.gov ↗ · Advanced Renal Cancer	Phase 3	Active, closed	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer NCT04807166 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Fallopian Tube Neoplasms, Neoplasms by Site	Phase 2	Active, closed	Wenjun Cheng	China
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma NCT05193617 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma NCT05220267 · ClinicalTrials.gov ↗ · Non Clear Cell Renal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
Anlotinib Capsules in the Treatment for IPF/PF-ILDs NCT05828953 · ClinicalTrials.gov ↗ · Interstitial Lung Diseases	Phase 2	Active, closed	First Affiliated Hospital of Wenzhou Medical University	China
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression NCT06939452 · ClinicalTrials.gov ↗ · Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	Phase 2	Active, closed	Yongxu Jia	China
Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer NCT07635290 · ClinicalTrials.gov ↗ · Previously Treated, Advanced, Biliary Tract Cancers	Phase 2	Active, closed	West China Hospital	China
Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC NCT07703228 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV, Second-line Therapy	Phase 2	Active, closed	Nanfang Hospital, Southern Medical University	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Anlotinib

87 conditions

Breast Cancer4 Nasopharyngeal Carcinoma3 Neoadjuvant Therapy2 Non-Small Cell Lung Cancer2 Biliary Tract Cancer2 Metastatic Pancreatic Cancer2 Non-small Cell Lung Cancer2 Head and Neck Squamous Cell Carcinoma1PD-L11Anlotinib1HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases1Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line1

All 87 conditions

Condition (as registered)	Trials
Breast Cancer	4
Nasopharyngeal Carcinoma	3
Neoadjuvant Therapy	2
Non-Small Cell Lung Cancer	2
Biliary Tract Cancer	2
Metastatic Pancreatic Cancer	2
Non-small Cell Lung Cancer	2
Head and Neck Squamous Cell Carcinoma	1
PD-L1	1
Anlotinib	1
HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases	1
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line	1
Locally Advanced Non-Small Cell Lung Cancer	1
Thoracic Radiotherapy	1
Safety	1
Previously Treated, Advanced	1
Biliary Tract Cancers	1
Advanced Renal Cancer	1
Soft Tissue Sarcoma	1
Doxorubicin	1
Radiotherapy	1
Thymic Carcinoma	1
Thymoma	1
Advanced Esophageal Squamous Cell Carcinoma	1
Esophageal Carcinoma	1
Bile Duct Carcinoma	1
Gall Bladder Cancer	1
Cholangiocarcinoma	1
Solid Tumor	1
Precision Medicine	1
Ovarian Neoplasms	1
Fallopian Tube Neoplasms	1
Neoplasms by Site	1
Genital Neoplasms, Female	1
Advanced Non-small Cell Lung Cancer	1
Extensive-stage Small Cell Lung Cancer	1
Mesothelioma, Malignant	1
Mesothelioma, Malignant Pleural	1
Mesothelioma Malignant Advanced	1
Triple Negative Breast Cancer	1
Cervical Cancer	1
Non-small Cell Lung Caner	1
KRAS-mutated	1
Metastasis	1
Previous Treamted	1
TNBC, Triple Negative Breast Cancer	1
Interstitial Lung Diseases	1
Whole-Brain Radiotherapy	1
Rhabdomyosarcoma Recurrent	1
Maintenance Treatment	1
Thyroid Neoplasms	1
Craniopharyngiomas	1
Large-Cell Neuroendocrine Carcinoma of the Lung	1
Extrapulmonary Neuroendocrine Carcinoma	1
NSCLC	1
Locally Advanced Pancreatic Cancer	1
SCLC, Limited Stage	1
Sarcoma	1
Pancreatic Cancer	1
First-line	1
Small Cell Lung Cancer Recurrent	1
ESCC	1
Breast Neoplasm	1
Breast Tumors	1
Triple-Negative Breast Cancer (TNBC)	1
Small Cell Lung Cancer Limited Stage	1
Adenoid Cystic Carcinoma	1
Small Cell Lung Cancer	1
Esophageal Squamous Cell Carcinoma	1
Non-small-cell Lung Cancer	1
Non Clear Cell Renal Carcinoma	1
Rhabdomyosarcoma	1
Solid Tumors	1
Children	1
Adolescents	1
Unresectable Hepatocellular Carcinoma	1
Esophageal Cancer	1
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	1
NSCLC (Advanced Non-small Cell Lung Cancer)	1
NSCLC Stage IIIB~IV	1
Second-line Therapy	1
Metastases	1
Locally Advanced Thyroid Gland Carcinoma	1
Locally Advanced or Metastatic Renal Cell Carcinoma	1
Second Line Treatment	1
Chemotherapy	1
Tyrosine Kinase Inhibitor	1

By country register

Register	Trials	Recruiting
Clinical trials in China	59	32

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Anlotinib trials

How many clinical trials are testing Anlotinib?

59 current trials in our China register name Anlotinib as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Anlotinib trials recruiting patients?

Yes. 32 of the 59 trials are recruiting: 32 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Anlotinib clinical trials?

Sun Yat-sen University (7), Fudan University (5), Tianjin Medical University Cancer Institute and Hospital (4) and Hunan Province Tumor Hospital (3), among 36 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Anlotinib works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anlotinib works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anlotinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Anlotinib clinical trials